MicroRNA‑382‑5p inhibits osteosarcoma development and progression by negatively regulating VEZF1 expression

Wu,Hui; Luo,Yu-Xi; Hu,Wen; Zhao,Mao-Lin; Bie,Jun; Yang,Mi; Pan,Rongqiang; Huang,Nan-Xiang; Feng,Gang; Liu,Kang; Song,Guiqin

doi:10.3892/ol.2021.13013

MicroRNA‑382‑5p inhibits osteosarcoma development and progression by negatively regulating VEZF1 expression

Authors:
- Hui Wu
- Yu-Xi Luo
- Wen Hu
- Mao-Lin Zhao
- Jun Bie
- Mi Yang
- Rongqiang Pan
- Nan-Xiang Huang
- Gang Feng
- Kang Liu
- Guiqin Song
View Affiliations

Affiliations: Department of Orthopedics, Nanchong Central Hospital, The Second Clinical Institute of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China, The First Clinical College, Anhui Medical University, Hefei, Anhui 230032, P.R. China, School of Medical Imaging, North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China, Oncology Department, Nanchong Central Hospital, The Second Clinical Institute of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China, Department of Pediatric Surgery, Nanchong Central Hospital, The Second Clinical Institute of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China, Institute of Tissue Engineering and Stem Cells, Nanchong Central Hospital, The Second Clinical Institute of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China, School of Basic Medicine, North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China
Published online on: August 27, 2021 https://doi.org/10.3892/ol.2021.13013
Article Number: 752
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human osteosarcoma is the most frequent malignant primary bone tumor that mainly occurs in young adults and children. MicroRNAs (miRNAs/miRs) are abnormally expressed in human osteosarcoma and contribute to osteosarcoma initiation and development. The present study aimed to investigate the role of miR‑382‑5p in the nosogenesis of osteosarcoma and to identify a novel target for osteosarcoma treatment. miR‑382‑5p expression was detected in human osteosarcoma clinical tissues and cell lines, including 143B, U2OS and MG63, via reverse transcription‑quantitative PCR analysis. Multiple bioinformatic prediction toowe used to identify the potential target genes of miR‑382‑5p and vascular endothelial zinc finger 1 (VEZF1), which were validated via the dual‑luciferase reporter assay. MG63 and U2OS cells were transfected with miR‑382‑5p mimics. The Cell Counting Kit‑8 assay was performed to assess cell proliferation, while the Transwell assay was performed to assess migration and invasion. Cell colony formation was measured via crystal violet staining, and apoptosis was assessed via Annexin V/propidium iodide staining. The wound healing assay was performed to assess the migratory ability of U2OS and MG63 cells. Antitumor effects of miR‑382‑5p were evaluated in nude mice xenografts using U2OS cells. The results demonstrated that miR‑382‑5p expression was markedly downregulated in human osteosarcoma tissues and cell lines compared with adjacent normal tissues. Transfection of miR‑382‑5p mimics into MG63 and U2OS cells significantly inhibited the malignant behaviors of cells, including decreased proliferation, migration, diminished colony formation and invasion, and promoted osteosarcoma cell apoptosis. Bioinformatics prediction indicated that VEZF1 is a direct target gene of miR‑382‑5p. Overexpression of VEZF1 restored osteosarcoma tumor development inhibited by miR‑382‑5p in vivo. In addition, overexpression of miR‑382‑5p restrained the growth of xenograft osteosarcoma in nude mice following co‑transfection, and overexpression of VEZF1 attenuated the inhibitory effect of miR‑382‑5p in nude mice. miR‑382‑5p acted as a tumor suppressor gene and inhibited the malignant biological behaviors of human osteosarcoma cells and functions associated with directly targeting VEZF1. Taken together, these results suggest that the miR‑382‑5p/VEZF1 interaction has an important role in osteosarcoma development and progression, and thus may be used as a diagnostic and therapeutic target for osteosarcoma.

View Figures

View References

1	Broadhead ML, Clark JC, Myers DE, Dass CR and Choong PF: The molecular pathogenesis of osteosarcoma: A review. Sarcoma. 2011:9592482011. View Article : Google Scholar : PubMed/NCBI
2	Yang J and Zhang W: New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol. 25:398–406. 2013. View Article : Google Scholar : PubMed/NCBI
3	Kansara M, Teng MW, Smyth MJ and Thomas DM: Translational biology of osteosarcoma. Nat Rev Cancer. 14:722–735. 2014. View Article : Google Scholar : PubMed/NCBI
4	Ottaviani G and Jaffe N: The epidemiology of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
5	Wu CC, Beird HC, Andrew Livingston J, Advani S, Mitra A, Cao S, Reuben A, Ingram D, Wang WL, Ju Z, et al: Immuno-genomic landscape of osteosarcoma. Nat Commun. 11:10082020. View Article : Google Scholar : PubMed/NCBI
6	Rytting M, Pearson P, Raymond AK, Ayala A, Murray J, Yasko AW, Johnson M and Jaffe N: Osteosarcoma in preadolescent patients. Clin Orthop Relat Res. 39–50. 2000. View Article : Google Scholar : PubMed/NCBI
7	Petrilli AS, de Camargo B, Filho VO, Bruniera P, Brunetto AL, Jesus-Garcia R, Camargo OP, Pena W, Péricles P, Davi A, et al: Results of the Brazilian osteosarcoma treatment group studies III and IV: Prognostic factors and impact on survival. J Clin Oncol. 24:1161–1168. 2006. View Article : Google Scholar : PubMed/NCBI
8	Hosseinahli N, Aghapour M, Duijf PHG and Baradaran B: Treating cancer with microRNA replacement therapy: A literature review. J Cell Physiol. 233:5574–5588. 2018. View Article : Google Scholar : PubMed/NCBI
9	Aredia F and Scovassi AI: A new function for miRNAs as regulators of autophagy. Future Med Chem. 9:25–36. 2017. View Article : Google Scholar : PubMed/NCBI
10	Song B, Wang Y, Xi Y, Kudo K, Bruheim S, Botchkina GI, Gavin E, Wan Y, Formentini A, Kornmann M, et al: Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene. 28:4065–4074. 2009. View Article : Google Scholar : PubMed/NCBI
11	Naeli P, Yousefi F, Ghasemi Y, Savardashtaki A and Mirzaei H: The role of MicroRNAs in lung cancer: Implications for diagnosis and therapy. Curr Mol Med. 20:90–101. 2020. View Article : Google Scholar : PubMed/NCBI
12	Martens-Uzunova ES, Bottcher R, Croce CM, Jenster G, Visakorpi T and Calin GA: Long noncoding RNA in prostate, bladder, and kidney cancer. Eur Urol. 65:1140–1151. 2014. View Article : Google Scholar : PubMed/NCBI
13	Zheng Z, Ding M, Ni J, Song D, Huang J and Wang J: miR-142 acts as a tumor suppressor in osteosarcoma cell lines by targeting Rac1. Oncol Rep. 33:1291–1299. 2015. View Article : Google Scholar : PubMed/NCBI
14	Qu Q, Chu X and Wang P: MicroRNA-195-5p suppresses osteosarcoma cell proliferation and invasion by suppressing naked cuticle homolog 1. Cell Biol Int. 41:287–295. 2017. View Article : Google Scholar : PubMed/NCBI
15	Wang Y, Ma Z, Kan P and Zhang B: The diagnostic value of serum miRNA-221-3p, miRNA-382-5p, and miRNA-4271 in ischemia stroke. J Stroke Cerebrovasc Dis. 26:1055–1060. 2017. View Article : Google Scholar : PubMed/NCBI
16	Zhang X, Zhao H, Zhang Y, Yang X, Zhang J, Yi M and Zhang C: The MicroRNA-382-5p/MXD1 axis relates to breast cancer progression and promotes cell malignant phenotypes. J Surg Res. 246:442–449. 2020. View Article : Google Scholar : PubMed/NCBI
17	Tan H, He Q, Gong G, Wang Y, Li J, Wang J, Zhu D and Wu X: miR-382 inhibits migration and invasion by targeting ROR1 through regulating EMT in ovarian cancer. Int J Oncol. 48:181–190. 2016. View Article : Google Scholar : PubMed/NCBI
18	Shan N, Shen L, Wang J, He D and Duan C: miR-153 inhibits migration and invasion of human non-small-cell lung cancer by targeting ADAM19. Biochem Biophys Res Commun. 456:385–391. 2015. View Article : Google Scholar : PubMed/NCBI
19	Wu Z, He B, He J and Mao X: Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer. Prostate. 73:596–604. 2013. View Article : Google Scholar : PubMed/NCBI
20	Paraskevopoulou MD, Vlachos IS, Karagkouni D, Georgakilas G, Kanellos I, Vergoulis T, Zagganas K, Tsanakas P, Floros E, Dalamagas T and Hatzigeorgiou AG: DIANA-LncBase v2: Indexing microRNA targets on non-coding transcripts. Nucleic Acids Res. 44(D1): D231–D238. 2016. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Lee JH, Kim C, Baek SH, Ko JH, Lee SC, Yang WM, Um JY, Sethi G and Ahn KS: Capsazepine inhibits JAK/STAT3 signaling, tumor growth, and cell survival in prostate cancer. Oncotarget. 8:17700–17711. 2017. View Article : Google Scholar : PubMed/NCBI
23	Sticht C, De La Torre C, Parveen A and Gretz N: miRWalk: An online resource for prediction of microRNA binding sites. PLoS One. 13:e02062392018. View Article : Google Scholar : PubMed/NCBI
24	Rennie W, Kanoria S, Liu C, Mallick B, Long D, Wolenc A, Carmack CS, Lu J and Ding Y: STarMirDB: A database of microRNA binding sites. RNA Biol. 13:554–560. 2016. View Article : Google Scholar : PubMed/NCBI
25	Zhu HF, Wang YH, Liu D, Sun XQ and Wang FR: Vanadium rutin complex sensitizes breast cancer cells via modulation of p53/Bax/Bcl2/VEGF correlated with apoptotic events. Acta Pol Pharm Drug Res. 77:89–98. 2020.
26	Lee RC, Feinbaum RL and Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
27	Nugent M: MicroRNA function and dysregulation in bone tumors: The evidence to date. Cancer Manag Res. 6:15–25. 2014. View Article : Google Scholar : PubMed/NCBI
28	Li S, Fu H, Wang Y, Tie Y, Xing R, Zhu J, Sun Z, Wei L and Zheng X: MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma. Hepatology. 49:1194–1202. 2009. View Article : Google Scholar : PubMed/NCBI
29	Vishnol A and Rani S: miRNA biogenesis and regulation of disease: An overview. Methods Mol Biol. 1509:1–10. 2017. View Article : Google Scholar : PubMed/NCBI
30	Reddy KB: MicroRNA (miRNA) in cancer. Cancer Cell Int. 15:382015. View Article : Google Scholar : PubMed/NCBI
31	Ho JY, Hsu RJ, Liu JM, Chen SC, Liao GS, Gao HW and Yu CP: MicroRNA-382-5p aggravates breast cancer progression by regulating the RERG/Ras/ERK signaling axis. Oncotarget. 8:22443–22459. 2017. View Article : Google Scholar : PubMed/NCBI
32	Wang J, Chen C, Yan X and Wang P: The role of miR-382-5p in glioma cell proliferation, migration and invasion. Onco Targets Ther. 12:4993–5002. 2019. View Article : Google Scholar : PubMed/NCBI
33	Xu M, Jin H, Xu CX, Sun B, Song ZG, Bi WZ and Wang Y: miR-382 inhibits osteosarcoma metastasis and relapse by targeting Y box-binding protein 1. Mol Ther. 23:89–98. 2015. View Article : Google Scholar : PubMed/NCBI
34	Wang L, Wang P, Su X and Zhao B: Circ_0001658 promotes the proliferation and metastasis of osteosarcoma cells via regulating miR-382-5p/YB-1 axis. Cell Biochem Funct. 38:77–86. 2020. View Article : Google Scholar : PubMed/NCBI
35	Xiao Y, Li C, Wang H and Liu Y: LINC00265 targets miR-382-5p to regulate SAT1, VAV3 and angiogenesis in osteosarcoma. Aging (Albany NY). 12:20212–20225. 2020.PubMed/NCBI
36	Kobayashi E, Hornicek FJ and Duan Z: MicroRNA involvement in osteosarcoma. Sarcoma. 2012:3597392012. View Article : Google Scholar : PubMed/NCBI
37	Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 20:776–790. 2002. View Article : Google Scholar : PubMed/NCBI
38	Nugent M: microRNA and bone cancer. Adv Exp Med Biol. 889:201–230. 2015. View Article : Google Scholar : PubMed/NCBI
39	Wu L and Qu X: Cancer biomarker detection: Recent achievements and challegenges. Chem Soc Rev. 44:2963–2997. 2015. View Article : Google Scholar : PubMed/NCBI
40	Wang XX, Ye FG, Zhang J, Li JJ, Chen QX, Lin PY and Song CG: Serum miR-4530 sensitizes breast cancer to neoadjuvant chemotherapy by suppressing RUNX2. Cancer Manag Res. 10:4393–4400. 2018. View Article : Google Scholar : PubMed/NCBI
41	Sampson VB, Yoo S, Kumar A, Vetter NS and Kolb EA: MicroRNAs and potential targets in osteosarcoma: Review. Front Pediatr. 3:692015. View Article : Google Scholar : PubMed/NCBI
42	AlAbdi L, He M, Yang Q, Norvil AB and Gowher H: The transcription factor Vezf1 represses the expression of the antiangiogenic factor Cited2 in endothelial cells. J Biol Chem. 293:11109–11118. 2018. View Article : Google Scholar : PubMed/NCBI
43	He M, Yang Q, Norvil AB, Sherris D and Gowher H: Characterization of small molecules inhibiting the pro-angiogenic activity of the zinc finger transcription factor Vezf1. Molecules. 23:16152018. View Article : Google Scholar : PubMed/NCBI
44	Gerald D, Adini I, Shechter S, Prendergast GC, Klagsbrun M, Stuhlmann H, Rigby AC, Nagy JA and Benjamin LE: RhoB controls coordination of adult angiogenesis and lymphangiogenesis following injury by regulating VEZF1-mediated transcription. Nat Commun. 4:28242013. View Article : Google Scholar : PubMed/NCBI
45	Yin R, Guo L, Gu J, Li C and Zhang W: Over expressing miR-19b-1 suppress breast cancer growth by inhibiting tumor microenvironment induced angiogenesis. Int J Biochem Cell Biol. 97:43–51. 2018. View Article : Google Scholar : PubMed/NCBI
46	Ahmed M, Lai TH, Zada S, Hwang JS, Pham TM, Yun M and Kim DR: Functional linkage of RKIP to the epithelial to mesenchymal transition and autophagy during the development of prostate cancer. Cancers (Basel). 10:2732018. View Article : Google Scholar : PubMed/NCBI